KBY Biotech Indexv0.0.34
Search
← Pipeline|NAT-IIT-995

NAT-IIT-995

Approved
By National Univ Hospital
Source: Trial-derived·Trials: 1
Modality
Peptide
MOA
BCMA ADC
Target
TNFα
Pathway
Incretin
MCC
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
~Dec 2018
→ ~Mar 2020
Phase 3
~Jun 2020
→ ~Sep 2021
NDA/BLA
~Dec 2021
→ ~Mar 2023
Approved
Jun 2023
→ Dec 2027
ApprovedCurrent
NCT05019014
1,200 pts·MCC
2023-06→2027-12·Terminated
1,200 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2027-12-241.7y awayPh3 Readout· MCC
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Approved
Termina…
Catalysts
Ph3 Readout
2027-12-24 · 1.7y away
MCC
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT05019014ApprovedMCCTerminated1200eGFR
Competitors (10)
DrugCompanyPhaseTargetMOA
ABB-3951AbbViePhase 2/3TNFαCDK2i
AZN-3724AstraZenecaPreclinicalPSMABCMA ADC
OlpatinibGSKPreclinicalPD-L1BCMA ADC
GIL-9779Gilead SciencesPhase 1IL-17ABCMA ADC
GIL-6239Gilead SciencesPhase 2TNFαCGRPant
MRN-8225ModernaPreclinicalTNFαSGLT2i
SovanaritideArgenxPhase 3TNFαBETi
369-4107Hansoh PharmaPhase 2TNFαSHP2i
SematenlimabSamsung BiologicsPhase 3PI3KαBCMA ADC
VKT-4052Viking TherapeuticsPhase 2/3TNFαWRNi